HK Stock Market Move | MEDBOT-B (02252) rose over 3% before the results were released. The company expects its revenue to increase by 120% year-on-year last year.

MEDBOT-B(02252) pre-performance rose by more than 3%, as of press release, up 3.64%, reporting 25.06 Hong Kong dollars, with a turnover of 2.06 billion Hong Kong dollars. On the news side, Siasun Robot & Automation plans to hold a board meeting on March 26 to consider and approve the full-year performance and announcement of the group ending on December 31, 2025. The company previously disclosed that it expects the company's revenue for the year ending December 31, 2025 to increase by about 110% to 120% year-on-year, with adjusted net loss not exceeding 240 million yuan, a decrease of over 50% year-on-year. The substantial increase in revenue is mainly due to the breakthrough progress in commercialization of the company's core product, the Tumai endoscopic surgery Siasun Robot & Automation, with rapid sales growth, especially significant results in overseas markets, with overseas market orders exceeding over a hundred units for the year, and overseas market sales revenue more than five times higher than last year.